Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.41 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.41 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789433 | 1.00 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL24425080 | 0.88 | MGLL (0.45) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL7895094 | 0.83 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29956269 | 0.83 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL206793 | 0.83 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL1231962 | 0.83 | KIF11 (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29525231 | 0.83 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL177526 | 0.81 | TTR (0.50) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL3790569 | 0.81 | MGLL (0.47) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL20475565 | 0.81 | MGLL (0.47) | MGLLTRPV6ORAI1ORAI2ORAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240855-B2 | Pyrrolopyrazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | MGLL 2748/4885TRPV6 1237/4885ORAI1 2414/4885 |
| US-12240855-B2 | Pyrrolopyrazole derivative | PTDSS1, PTDSS2, SMPD1 | MGLL 2748/4885TRPV6 1237/4885ORAI1 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.